Nephrogen

Kidney and pancreatic genetic diseases lack effective curative treatments and have no approved gene-based therapies due in part to inadequate organ-targeted gene delivery.

Nephrogen develops curative genetic medicines using an AI- and high-throughput-screening platform to engineer safer, more efficient, lower-cost gene delivery vehicles that reach the kidney and pancreas.

Biopharma companies and clinical healthcare providers developing and administering gene therapies for kidney and pancreatic diseases.